Legend Strategy International Holdings Group Company Limited Announces Completion of Strategic Acquisition

Key Highlights

• Completion of Acquisition: Legend Strategy International Holdings Group Company Limited (“Legend Strategy”) has officially completed its acquisition as per the Sale and Purchase Agreement.
• Equity Stake Acquired: The Group now holds a significant 37.5% equity interest in Beisheng Biotechnology.
• Date of Completion: The acquisition was finalized on 6 March 2026.
• Conditions Precedent Satisfied: All conditions required for completion under the Sale and Purchase Agreement have been met.

Details for Shareholders

The completion of this acquisition is a material event for Legend Strategy. By acquiring a substantial stake in Beisheng Biotechnology, the company is positioning itself for potential growth in the biotechnology sector, which may have direct implications for shareholders.

• Potential Share Price Impact: The acquisition of a 37.5% interest in Beisheng Biotechnology could be viewed positively by the market, as it provides Legend Strategy with exposure to a growing industry and potential new revenue streams.
• Strategic Positioning: This move is part of Legend Strategy’s broader strategy to diversify its holdings and strengthen its portfolio in the biotechnology space.
• Price Sensitivity: Any developments or performance improvements in Beisheng Biotechnology could significantly impact Legend Strategy’s financial results, which may be reflected in its share price.
• Board Composition: As of the announcement date, the Board comprises Ms. Lee Tsz Yan (Executive Director), Mr. Cheung Ching Ho and Mr. Hu Xinglong (Non-Executive Directors), and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard, and Mr. So Yin Wai (Independent Non-Executive Directors).

Additional Information

The completion announcement follows prior disclosures made by Legend Strategy in December 2025 and March 2026 regarding the acquisition process. Now that the transaction has closed, investors should monitor further communications from the company for updates on the integration and performance of Beisheng Biotechnology.

The acquisition is likely to be considered price-sensitive given its potential to impact future earnings and strategic direction. Shareholders are advised to consider this development when making investment decisions.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information provided is based on official company disclosures and may be subject to change.

View LEGEND STRAT Historical chart here